Literature DB >> 23896508

Update on therapeutic options for multiple sclerosis.

Matthew McCoyd1.   

Abstract

Multiple sclerosis (MS) is one of the most common neurologic disorders that affects young people. The disorder has long been associated with clinical relapses and a disabling course. However, there has been a rapid expansion in the available treatment options for MS, and new insights into existing therapies, as decades of research has begun to produce tangible treatment results leading to newly approved an emerging therapies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alemtuzumab (Lemtrada); BG-12 (Tecfidera); Fingolimod (Gilenya); McDonald criteria; Natalizumab (Tysabri); Teriflunomide (Aubagio); Vitamin D

Mesh:

Substances:

Year:  2013        PMID: 23896508     DOI: 10.1016/j.ncl.2013.03.010

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  3 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

2.  Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report.

Authors:  Concetta De Pasquale; Maria Luisa Pistorio; Massimiliano Veroux; Alessia Giaquinta; Pierfrancesco Veroux; Michele Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-11       Impact factor: 2.570

3.  Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients.

Authors:  Rodica Padureanu; Carmen Valeria Albu; Ionica Pirici; Radu Razvan Mititelu; Mihaela Simona Subtirelu; Razvan Aurelian Turcu-Stiolica; Harri Sintonen; Vlad Padureanu; Adina Turcu-Stiolica
Journal:  J Clin Med       Date:  2020-05-05       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.